News | 04 February 2022
Pfizer Q3FY22 PAT at Rs 143.91 crore
The company has reported standalone financial results for the period ended December 31, 2021.
The company has reported standalone financial results for the period ended December 31, 2021.
Sun Pharma’s Q3FY22 operational performance was in line with I-direct estimates with sustained momentum and good growth across businesses
Highest safety and efficacy of Sputnik V confirmed during clinical trials and in real-world use in more than 60 countries around the world
The company has reported total income of Rs. 3715.8 crores during the quarter ended December 31, 2021
The need is to vaccinate people who have not contracted Covid-19
Caplin Point Laboratories has reported consolidated financial results for the period ended December 31, 2021.
The acquisition will allow Dr. Reddy's to build on Nimbus Health's strengths and introduce medical cannabis-based medicines as a promising treatment option for patients
The vaccine will be priced at Rs. 265 per dose and the applicator being offered at Rs. 93 per dose excluding GST
The pharma division’s domestic business generated turnover of Rs. 219.85 crore for the last financial year
It will enable the company to branch out to new geographies and strengthen its presence in South Africa
Pegfilgrastim is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherapy
A National Tele Mental Health Programme is being launched to address mental health issues. We spoke to healthcare industry leaders who shared their outlook
Fiscal support in line with what is available in key innovation hubs such as USA and China will drive the next leg of drug discovery in India
ICICI Direct analysis of Dr Reddy’s Q3FY22 results
The audit is a PAI for two of its product applications filed from this facility
ICICI Direct’s analysis of Cipla’s Q3FY22 results
Sun Pharmaceutical Industries has reported consolidated financial results for the period ended December 31, 2021
In the April-September 2021 period, the FDI inflows continued to be buoyant at Rs 4,413 crore, growing at the rate of 53 per cent over the same period in 2020-21
Intranasal vaccines are easier to administer in mass immunisation campaigns and help reduce or stop transmission
The management guided for ARV API & formulation demand to be normalised from Q4FY22 and reiterated the aspiration of US $ 1 billion in sales by FY23: ICICI Direct
Subscribe To Our Newsletter & Stay Updated
